This report focuses on the global Hematologic Malignancies status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hematologic Malignancies development in United States, Europe and China.
In 2017, the global Hematologic Malignancies market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025.
The key players covered in this study
Pfizer, Inc.
F. Hoffmann-LA Roche ltd
Sanofi-Aventis
Bristol-Myers Squibb Company
AbbVie, Inc.
Novartis AG
GlaxoSmithKline PLC
Celgene Corporation
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical Company limited
Market segment by Type, the product can be split into
Leukemia
Lymphoma
Multiple Myeloma
Others
Market segment by Application, split into
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Hematologic Malignancies status, future forecast, growth opportunity, key market and key players.
To present the Hematologic Malignancies development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Hematologic Malignancies are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Hematologic Malignancies Market Size Growth Rate by Type (2013-2025)
1.4.2 Leukemia
1.4.3 Lymphoma
1.4.4 Multiple Myeloma
1.4.5 Others
1.5 Market by Application
1.5.1 Global Hematologic Malignancies Market Share by Application (2013-2025)
1.5.2 Chemotherapy
1.5.3 Radiotherapy
1.5.4 Immunotherapy
1.5.5 Stem Cell Transplantation
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Hematologic Malignancies Market Size
2.2 Hematologic Malignancies Growth Trends by Regions
2.2.1 Hematologic Malignancies Market Size by Regions (2013-2025)
2.2.2 Hematologic Malignancies Market Share by Regions (2013-2018)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
3 Market Share by Key Players
3.1 Hematologic Malignancies Market Size by Manufacturers
3.1.1 Global Hematologic Malignancies Revenue by Manufacturers (2013-2018)
3.1.2 Global Hematologic Malignancies Revenue Market Share by Manufacturers (2013-2018)
3.1.3 Global Hematologic Malignancies Market Concentration Ratio (CR5 and HHI)
3.2 Hematologic Malignancies Key Players Head office and Area Served
3.3 Key Players Hematologic Malignancies Product/Solution/Service
3.4 Date of Enter into Hematologic Malignancies Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Hematologic Malignancies Market Size by Type (2013-2018)
4.2 Global Hematologic Malignancies Market Size by Application (2013-2018)
5 United States
5.1 United States Hematologic Malignancies Market Size (2013-2018)
5.2 Hematologic Malignancies Key Players in United States
5.3 United States Hematologic Malignancies Market Size by Type
5.4 United States Hematologic Malignancies Market Size by Application
6 Europe
6.1 Europe Hematologic Malignancies Market Size (2013-2018)
6.2 Hematologic Malignancies Key Players in Europe
6.3 Europe Hematologic Malignancies Market Size by Type
6.4 Europe Hematologic Malignancies Market Size by Application
7 China
7.1 China Hematologic Malignancies Market Size (2013-2018)
7.2 Hematologic Malignancies Key Players in China
7.3 China Hematologic Malignancies Market Size by Type
7.4 China Hematologic Malignancies Market Size by Application
8 Japan
8.1 Japan Hematologic Malignancies Market Size (2013-2018)
8.2 Hematologic Malignancies Key Players in Japan
8.3 Japan Hematologic Malignancies Market Size by Type
8.4 Japan Hematologic Malignancies Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Hematologic Malignancies Market Size (2013-2018)
9.2 Hematologic Malignancies Key Players in Southeast Asia
9.3 Southeast Asia Hematologic Malignancies Market Size by Type
9.4 Southeast Asia Hematologic Malignancies Market Size by Application
10 India
10.1 India Hematologic Malignancies Market Size (2013-2018)
10.2 Hematologic Malignancies Key Players in India
10.3 India Hematologic Malignancies Market Size by Type
10.4 India Hematologic Malignancies Market Size by Application
11 Central & South America
11.1 Central & South America Hematologic Malignancies Market Size (2013-2018)
11.2 Hematologic Malignancies Key Players in Central & South America
11.3 Central & South America Hematologic Malignancies Market Size by Type
11.4 Central & South America Hematologic Malignancies Market Size by Application
12 International Players Profiles
12.1 Pfizer, Inc.
12.1.1 Pfizer, Inc. Company Details
12.1.2 Company Description and Business Overview
12.1.3 Hematologic Malignancies Introduction
12.1.4 Pfizer, Inc. Revenue in Hematologic Malignancies Business (2013-2018)
12.1.5 Pfizer, Inc. Recent Development
12.2 F. Hoffmann-LA Roche ltd
12.2.1 F. Hoffmann-LA Roche ltd Company Details
12.2.2 Company Description and Business Overview
12.2.3 Hematologic Malignancies Introduction
12.2.4 F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2013-2018)
12.2.5 F. Hoffmann-LA Roche ltd Recent Development
12.3 Sanofi-Aventis
12.3.1 Sanofi-Aventis Company Details
12.3.2 Company Description and Business Overview
12.3.3 Hematologic Malignancies Introduction
12.3.4 Sanofi-Aventis Revenue in Hematologic Malignancies Business (2013-2018)
12.3.5 Sanofi-Aventis Recent Development
12.4 Bristol-Myers Squibb Company
12.4.1 Bristol-Myers Squibb Company Company Details
12.4.2 Company Description and Business Overview
12.4.3 Hematologic Malignancies Introduction
12.4.4 Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2013-2018)
12.4.5 Bristol-Myers Squibb Company Recent Development
12.5 AbbVie, Inc.
12.5.1 AbbVie, Inc. Company Details
12.5.2 Company Description and Business Overview
12.5.3 Hematologic Malignancies Introduction
12.5.4 AbbVie, Inc. Revenue in Hematologic Malignancies Business (2013-2018)
12.5.5 AbbVie, Inc. Recent Development
12.6 Novartis AG
12.6.1 Novartis AG Company Details
12.6.2 Company Description and Business Overview
12.6.3 Hematologic Malignancies Introduction
12.6.4 Novartis AG Revenue in Hematologic Malignancies Business (2013-2018)
12.6.5 Novartis AG Recent Development
12.7 GlaxoSmithKline PLC
12.7.1 GlaxoSmithKline PLC Company Details
12.7.2 Company Description and Business Overview
12.7.3 Hematologic Malignancies Introduction
12.7.4 GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2013-2018)
12.7.5 GlaxoSmithKline PLC Recent Development
12.8 Celgene Corporation
12.8.1 Celgene Corporation Company Details
12.8.2 Company Description and Business Overview
12.8.3 Hematologic Malignancies Introduction
12.8.4 Celgene Corporation Revenue in Hematologic Malignancies Business (2013-2018)
12.8.5 Celgene Corporation Recent Development
12.9 Johnson & Johnson Services, Inc.
12.9.1 Johnson & Johnson Services, Inc. Company Details
12.9.2 Company Description and Business Overview
12.9.3 Hematologic Malignancies Introduction
12.9.4 Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2013-2018)
12.9.5 Johnson & Johnson Services, Inc. Recent Development
12.10 Takeda Pharmaceutical Company limited
12.10.1 Takeda Pharmaceutical Company limited Company Details
12.10.2 Company Description and Business Overview
12.10.3 Hematologic Malignancies Introduction
12.10.4 Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2013-2018)
12.10.5 Takeda Pharmaceutical Company limited Recent Development
13 Market Forecast 2018-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2018-2025)
13.10 Market Size Forecast by Application (2018-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
List of Tables and Figures
Table Hematologic Malignancies Key Market Segments
Table Key Players Hematologic Malignancies Covered
Table Global Hematologic Malignancies Market Size Growth Rate by Type 2013-2025 (Million US$)
Figure Global Hematologic Malignancies Market Size Market Share by Type 2013-2025
Figure Leukemia Figures
Table Key Players of Leukemia
Figure Lymphoma Figures
Table Key Players of Lymphoma
Figure Multiple Myeloma Figures
Table Key Players of Multiple Myeloma
Figure Others Figures
Table Key Players of Others
Table Global Hematologic Malignancies Market Size Growth by Application 2013-2025 (Million US$)
Figure Chemotherapy Case Studies
Figure Radiotherapy Case Studies
Figure Immunotherapy Case Studies
Figure Stem Cell Transplantation Case Studies
Figure Others Case Studies
Figure Hematologic Malignancies Report Years Considered
Table Global Hematologic Malignancies Market Size 2013-2025 (Million US$)
Figure Global Hematologic Malignancies Market Size and Growth Rate 2013-2025 (Million US$)
Table Global Hematologic Malignancies Market Size by Regions 2013-2025 (Million US$)
Table Global Hematologic Malignancies Market Size by Regions 2013-2018 (Million US$)
Table Global Hematologic Malignancies Market Share by Regions 2013-2018
Figure Global Hematologic Malignancies Market Share by Regions 2013-2018
Figure Global Hematologic Malignancies Market Share by Regions 2018
Table Market Top Trends
Table Global Hematologic Malignancies Revenue by Manufacturers (2013-2018) (Million US$)
Table Global Hematologic Malignancies Market Share by Manufacturers (2013-2018)
Figure Global Hematologic Malignancies Market Share by Manufacturers in 2018
Table Global Hematologic Malignancies Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Hematologic Malignancies Product/Solution/Service
Table Date of Enter into Hematologic Malignancies Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Hematologic Malignancies Market Size by Type (2013-2018) (Million US$)
Table Global Hematologic Malignancies Market Size Share by Type (2013-2018)
Figure Global Hematologic Malignancies Market Size Market Share by Type (2013-2018)
Table Global Hematologic Malignancies Market Size by Application (2013-2018) (Million US$)
Table Global Hematologic Malignancies Market Size Share by Application (2013-2018)
Figure Global Hematologic Malignancies Market Size Market Share by Application (2013-2018)
Figure Global Hematologic Malignancies Revenue Market Share by Application in 2017
Figure United States Hematologic Malignancies Market Size 2013-2018 (Million US$)
Table United States Key Players Hematologic Malignancies Revenue (2017-2018) (Million US$)
Table United States Key Players Hematologic Malignancies Market Share (2017-2018)
Table United States Hematologic Malignancies Market Size by Type (2013-2018) (Million US$)
Table United States Hematologic Malignancies Market Share by Type (2013-2018)
Table United States Hematologic Malignancies Market Size by Application (2013-2018) (Million US$)
Table United States Hematologic Malignancies Market Share by Application (2013-2018)
Figure Europe Hematologic Malignancies Market Size 2013-2018 (Million US$)
Table Europe Key Players Hematologic Malignancies Revenue (2017-2018) (Million US$)
Table Europe Key Players Hematologic Malignancies Market Share (2017-2018)
Table Europe Hematologic Malignancies Market Size by Type (2013-2018) (Million US$)
Table Europe Hematologic Malignancies Market Share by Type (2013-2018)
Table Europe Hematologic Malignancies Market Size by Application (2013-2018) (Million US$)
Table Europe Hematologic Malignancies Market Share by Application (2013-2018)
Figure China Hematologic Malignancies Market Size 2013-2018 (Million US$)
Table China Key Players Hematologic Malignancies Revenue (2017-2018) (Million US$)
Table China Key Players Hematologic Malignancies Market Share (2017-2018)
Table China Hematologic Malignancies Market Size by Type (2013-2018) (Million US$)
Table China Hematologic Malignancies Market Share by Type (2013-2018)
Table China Hematologic Malignancies Market Size by Application (2013-2018) (Million US$)
Table China Hematologic Malignancies Market Share by Application (2013-2018)
Figure Japan Hematologic Malignancies Market Size 2013-2018 (Million US$)
Table Japan Key Players Hematologic Malignancies Revenue (2017-2018) (Million US$)
Table Japan Key Players Hematologic Malignancies Market Share (2017-2018)
Table Japan Hematologic Malignancies Market Size by Type (2013-2018) (Million US$)
Table Japan Hematologic Malignancies Market Share by Type (2013-2018)
Table Japan Hematologic Malignancies Market Size by Application (2013-2018) (Million US$)
Table Japan Hematologic Malignancies Market Share by Application (2013-2018)
Figure Southeast Asia Hematologic Malignancies Market Size 2013-2018 (Million US$)
Table Southeast Asia Key Players Hematologic Malignancies Revenue (2017-2018) (Million US$)
Table Southeast Asia Key Players Hematologic Malignancies Market Share (2017-2018)
Table Southeast Asia Hematologic Malignancies Market Size by Type (2013-2018) (Million US$)
Table Southeast Asia Hematologic Malignancies Market Share by Type (2013-2018)
Table Southeast Asia Hematologic Malignancies Market Size by Application (2013-2018) (Million US$)
Table Southeast Asia Hematologic Malignancies Market Share by Application (2013-2018)
Figure India Hematologic Malignancies Market Size 2013-2018 (Million US$)
Table India Key Players Hematologic Malignancies Revenue (2017-2018) (Million US$)
Table India Key Players Hematologic Malignancies Market Share (2017-2018)
Table India Hematologic Malignancies Market Size by Type (2013-2018) (Million US$)
Table India Hematologic Malignancies Market Share by Type (2013-2018)
Table India Hematologic Malignancies Market Size by Application (2013-2018) (Million US$)
Table India Hematologic Malignancies Market Share by Application (2013-2018)
Figure Central & South America Hematologic Malignancies Market Size 2013-2018 (Million US$)
Table Central & South America Key Players Hematologic Malignancies Revenue (2017-2018) (Million US$)
Table Central & South America Key Players Hematologic Malignancies Market Share (2017-2018)
Table Central & South America Hematologic Malignancies Market Size by Type (2013-2018) (Million US$)
Table Central & South America Hematologic Malignancies Market Share by Type (2013-2018)
Table Central & South America Hematologic Malignancies Market Size by Application (2013-2018) (Million US$)
Table Central & South America Hematologic Malignancies Market Share by Application (2013-2018)
Table Pfizer, Inc. Company Details
Table Pfizer, Inc. Revenue in Hematologic Malignancies Business (2013-2018) (Million US$)
Figure Pfizer, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2013-2018)
Table Pfizer, Inc. Recent Development
Table F. Hoffmann-LA Roche ltd Company Details
Table F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2013-2018)(Million US$)
Figure F. Hoffmann-LA Roche ltd Revenue Growth Rate in Hematologic Malignancies Business (2013-2018)
Table F. Hoffmann-LA Roche ltd Recent Development
Table Sanofi-Aventis Company Details
Table Sanofi-Aventis Revenue in Hematologic Malignancies Business (2013-2018)(Million US$)
Figure Sanofi-Aventis Revenue Growth Rate in Hematologic Malignancies Business (2013-2018)
Table Sanofi-Aventis Recent Development
Table Bristol-Myers Squibb Company Company Details
Table Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2013-2018)(Million US$)
Figure Bristol-Myers Squibb Company Revenue Growth Rate in Hematologic Malignancies Business (2013-2018)
Table Bristol-Myers Squibb Company Recent Development
Table AbbVie, Inc. Company Details
Table AbbVie, Inc. Revenue in Hematologic Malignancies Business (2013-2018)(Million US$)
Figure AbbVie, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2013-2018)
Table AbbVie, Inc. Recent Development
Table Novartis AG Company Details
Table Novartis AG Revenue in Hematologic Malignancies Business (2013-2018)(Million US$)
Figure Novartis AG Revenue Growth Rate in Hematologic Malignancies Business (2013-2018)
Table Novartis AG Recent Development
Table GlaxoSmithKline PLC Company Details
Table GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2013-2018)(Million US$)
Figure GlaxoSmithKline PLC Revenue Growth Rate in Hematologic Malignancies Business (2013-2018)
Table GlaxoSmithKline PLC Recent Development
Table Celgene Corporation Company Details
Table Celgene Corporation Revenue in Hematologic Malignancies Business (2013-2018)(Million US$)
Figure Celgene Corporation Revenue Growth Rate in Hematologic Malignancies Business (2013-2018)
Table Celgene Corporation Recent Development
Table Johnson & Johnson Services, Inc. Company Details
Table Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2013-2018)(Million US$)
Figure Johnson & Johnson Services, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2013-2018)
Table Johnson & Johnson Services, Inc. Recent Development
Table Takeda Pharmaceutical Company limited Company Details
Table Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2013-2018)(Million US$)
Figure Takeda Pharmaceutical Company limited Revenue Growth Rate in Hematologic Malignancies Business (2013-2018)
Table Takeda Pharmaceutical Company limited Recent Development
Table Global Hematologic Malignancies Market Size by Regions (Million US$) 2018-2025
Figure Global Hematologic Malignancies Market Size Share by Regions (2018-2025)
Figure Global Hematologic Malignancies Market Size Share by Regions in 2025
Figure United States Hematologic Malignancies Market Size Forecast (2018-2025)(Million USD)
Figure Europe Hematologic Malignancies Market Size Forecast (2018-2025)(Million USD)
Figure China Hematologic Malignancies Market Size Forecast (2018-2025)(Million USD)
Figure Japan Hematologic Malignancies Market Size Forecast (2018-2025)(Million USD)
Figure Southeast Asia Hematologic Malignancies Market Size Forecast (2018-2025)(Million USD)
Figure India Hematologic Malignancies Market Size Forecast (2018-2025)(Million USD)
Figure Central & South America Hematologic Malignancies Market Size Forecast (2018-2025)(Million USD)
Table Global Hematologic Malignancies Market Size by Product (2018-2025) (Million US$)
Figure Global Hematologic Malignancies Market Size by Product (2018-2025)
Figure Global Hematologic Malignancies Market Size by Product in 2025
Table Global Hematologic Malignancies Market Size by Application (2018-2025) (Million US$)
Figure Global Hematologic Malignancies Market Size by Application (2018-2025)
Figure Global Hematologic Malignancies Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
